TRANSLINK
Defining the role of xeno-directed and autoimmune events in patients receiving animal-derived bioprosthetic heart valves
| Coordinatore | AZIENDA OSPEDALIERA DI PADOVA
Organization address
address: Via Giustiniani 1 contact info |
| Nazionalità Coordinatore | Italy [IT] |
| Totale costo | 7˙949˙030 € |
| EC contributo | 5˙996˙971 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-09-01 - 2017-08-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
AZIENDA OSPEDALIERA DI PADOVA
Organization address
address: Via Giustiniani 1 contact info |
IT (PADOVA) | coordinator | 718˙609.40 |
| 2 |
AVANTEA srl
Organization address
address: via Cabrini 12 contact info |
IT (Cremona) | participant | 931˙800.00 |
| 3 |
INSTITUT UNIV. DE CIENCIA I TECNOLOGIA SA
Organization address
address: CALLE ALVAREZ DE CASTRO 63 contact info |
ES (MOLLET DEL VALLES) | participant | 734˙940.00 |
| 4 |
CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
Organization address
address: Allee de l'Ile Gloriette 5 contact info |
FR (NANTES) | participant | 547˙746.00 |
| 5 |
INSTITUT CATALA DE LA SALUT
Organization address
address: GRAN VIA DE LES CORTS CATALANES 587 contact info |
ES (BARCELONA) | participant | 539˙993.60 |
| 6 |
TEL AVIV UNIVERSITY
Organization address
address: RAMAT AVIV contact info |
IL (TEL AVIV) | participant | 511˙923.60 |
| 7 |
GOETEBORGS UNIVERSITET
Organization address
address: VASAPARKEN contact info |
SE (GOETEBORG) | participant | 492˙532.00 |
| 8 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 345˙252.00 |
| 9 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 338˙856.00 |
| 10 |
FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE
Organization address
address: AVENIDA GRAN VIA HOSPITALET 199-203 contact info |
ES (L'HOSPITALET DE LLOBREGAT) | participant | 293˙788.40 |
| 11 |
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Organization address
address: "FRANKLIN STREET 1111, 12 FLOOR" contact info |
US (OAKLAND CA) | participant | 206˙250.00 |
| 12 |
UNIVERSITA DEGLI STUDI DI PADOVA
Organization address
address: VIA 8 FEBBRAIO 2 contact info |
IT (PADOVA) | participant | 197˙880.00 |
| 13 |
MIND THE BYTE SL
Organization address
address: CALLE MANSO 76 PRINCIPAL 1 contact info |
ES (BARCELONA) | participant | 137˙400.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'TRANSLINK is a project devoted to assessing the mid-to long-term risk factors and improve the outcome of animal (bovine/porcine)-derived Bioprosthetic Heart Valve (BHV) implants. 300,000 patients/year benefit from BHV, a major healthcare problem (second most frequent cardiac surgery). BHV clinical outcome suffers from late dysfunctions restricting their application to older recipients. Based on a retrospective (already computerised) and prospective cohort of approximately 3,000 BHV recipients and control patients from 3 large EU cardiac surgery groups, TRANSLINK aims primarily to establish the possible role of recipients' immune response (IR) against BHV as a major cause to mid- to-long term clinical dysfunction. Precise molecular analysis of preimplantation BVH sugar moieties will be performed. Possible indirect side-effects on BHV endocarditis and host vessels inflammation are secondary end points. Serial and trans-sectional blood samples will be dispatched to a battery of highly specialised partner groups for testing anti-Gal, -Neu5Gc and -hyaluronic acid antibodies (Ig) using both validated and newly designed screening tools, glycan array patterns, and macrophages/NK responses. Data will be crossed with clinical outcome scores. Project design aims at delivering comprehensive recommendations in the time-frame of the grant. Fundamental basic science progress in the field of carbohydrate antigens is also expected. Furthermore, prevention (BHV from engineered animal source lacking major antigens) and treatment (bioabsorbants of deleterious Ig) oriented remedies as well as prospective biomarkers of longterm BHV deterioration will be set up by three first-class SMEs. TRANSLINK may strongly impact the treatment of heart valve diseases by improving morbid-mortality in patients with heart valves diseases and increasing the indication of BHV to younger patients.'